Wedbush Expects Stronger Earnings for Viridian Therapeutics

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at Wedbush raised their Q1 2025 earnings per share estimates for Viridian Therapeutics in a report released on Thursday, February 27th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($1.01) for the quarter, up from their previous forecast of ($1.02). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.03) EPS, FY2026 earnings at ($4.43) EPS and FY2029 earnings at $11.84 EPS.

Several other research firms have also weighed in on VRDN. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada increased their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Finally, TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $15.23 on Monday. The stock’s 50-day simple moving average is $18.02 and its 200 day simple moving average is $19.70. The firm has a market capitalization of $1.21 billion, a PE ratio of -3.53 and a beta of 1.32. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC raised its position in shares of Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock worth $410,000 after acquiring an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL raised its position in shares of Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock worth $735,000 after acquiring an additional 1,106 shares during the last quarter. R Squared Ltd bought a new position in shares of Viridian Therapeutics during the fourth quarter worth about $26,000. Summit Investment Advisors Inc. raised its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, AlphaQuest LLC raised its position in shares of Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.